Life Sciences: Under the microscope
A single FDA question, a missed clinical endpoint, or a manufacturing snag can wipe billions off a market cap in minutes, and in life sciences that kind of volatility often comes with a second hit: a securities class action. We sit down with Kevin McRoy, Executive Vice President at RT Pro Exec and author of The D&O Diary, and John Connolly, Executive Managing Director at Howden USA, leading our North American life sciences practice, to unpack why biotech, pharma, and medical device companies remain such frequent targets, and why courts still dismiss these claims at a higher rate than in many other sectors. We dig into what the numbers really mean for leadership teams, investors, and D&O insurance buyers: the difference between a speculative developmental stage business and an actual fraud narrative, how the Private Securities Litigation Reform Act shapes pleading standards, and why scienter is often the hill plaintiffs struggle to climb. We also explore why more filings are landing in the Third Circuit and what makes that forum distinctive, from its familiarity with FDA-related complexity to its intolerance for selective or weak disclosure. If you work in life sciences, risk, legal, finance, or insurance, this is a clear-eyed guide to how these lawsuits form and how to reduce avoidable exposure.








